Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer

References

• WHODisease and injury country estimatesGenevaWorld Health Organization2009 Available from: http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/Accessed November 11, 2009
   Google Scholar
• MornoşCPetrescuLEarly detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twistCan J Physiol Pharmacol20139160160723889668
   PubMed Web of Science ®Google Scholar
• Von HoffDDLayardMWBasaPRisk factors for doxorubicin-induced congestive heart failureAnn Intern Med197991710717496103
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsCancer2003972869287912767102
   PubMed Web of Science ®Google Scholar
• SingalPKLiTKumarDDanelisenIIliskovicNAdriamycin-induced heart failure: mechanism and modulationMol Cell Biochem2000207778610888230
   PubMed Web of Science ®Google Scholar
• GyalaiKIAndorMTomescuMCBordejevicAMarincuISpeckle echocardiographic left atrial strain as predictor of atrial fibrillation recurrence in hypertensive patientsHealthmed20148705714
   Google Scholar
• HeimdalAStoylenATorpHSkjaerpeTReal-time strain rate imaging of the left ventricle by ultrasoundJ Am Soc Echocardiogr199811101310199812093
   PubMed Web of Science ®Google Scholar
• WeissRNebivolol: a novel beta-blocker with nitric oxide-induced vasodilatationVasc Health Risk Manag2006230330817326335
   PubMedGoogle Scholar
• VeverkaASalinasJLNebivolol in the treatment of chronic heart failureVasc Health Risk Manag2007364765418078016
   PubMedGoogle Scholar
• GroarkeJDNohriaAAnthracycline cardiotoxicity: a new paradigm for an old classicCirculation20151311946194925948539
   PubMed Web of Science ®Google Scholar
• EwerMSLippmanSMType II chemotherapy-related cardiac dysfunction: time to recognize a new entityJ Clin Oncol2005232900290215860848
   PubMed Web of Science ®Google Scholar
• VolkovaMRussellR3rdAnthracycline cardiotoxicity: prevalence, pathogenesis, and treatmentCurr Cardiol Rev2011721422022758622
   PubMedGoogle Scholar
• ShiYMoonMDawoodSMcManusBLiuPPMechanisms and management of doxorubicin cardiotoxicityHerz20113629630521656050
   PubMed Web of Science ®Google Scholar
• TodorovaVKMakhoulIDhakalIPolymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patientsOncol Res2017251223122928256194
   PubMed Web of Science ®Google Scholar
• HamoCEBloomMWCardinaleCCancer therapy-related cardiac dysfunction and heart failure. Part 2: prevention, treatment, guidelines, and future directionsCirc Heart Fail20169e00284326839395
   PubMed Web of Science ®Google Scholar
• DulinBAbrahamWTPharmacology of carvedilolAm J Cardiol20049336
   PubMed Web of Science ®Google Scholar
• NabatiMJanbabaiGBaghyariSEsmailiKYazdaniJCardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicityJ Cardiovasc Pharmacol20176927928528141699
   PubMed Web of Science ®Google Scholar
• KayaMGOzkanMGunebakmazOProtective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control studyInt J Cardiol20131672306231022727976
   PubMed Web of Science ®Google Scholar
• ChoeJYCombsABFolkersKPotentiation of the toxicity of adriamycin by propranololRes Commun Chem Pathol Pharmacol197821577580705032
   PubMedGoogle Scholar
• GeorgakopoulosPRoussouPMatsakasECardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-upAm J Hematol20108589489620872550
   PubMed Web of Science ®Google Scholar
• OretoLTodaroMCUmlandMMUse of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know?J Am Soc Echocardiogr2012251141115223000452
   PubMed Web of Science ®Google Scholar
• StoodleyPWRichardsDAHuiRTwo-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapyEur J Echocardiogr20111294595221965152
   PubMed Web of Science ®Google Scholar
• SawayaHSebagIAPlanaJCEarly detection and prediction of cardiotoxicity in chemotherapy-treated patientsAm J Cardiol20111071375138021371685
   PubMed Web of Science ®Google Scholar
• PalmeiraCMSerranoJKuehlDWWallaceKBPreferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicinBiochim Biophys Acta199713211011069332499
   PubMed Web of Science ®Google Scholar
• MimnaughEGTrushMABhatnagarMGramTEEnhancement of reactive oxygen-dependent mitochondrial membrane lipid per-oxidation by the anticancer drug adriamycinBiochem Pharmacol1985348478563977958
   PubMed Web of Science ®Google Scholar
• KangYJChenYYuAVoss-McCowanMEpsteinPNOverexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicityJ Clin Invest1997100150115069294117
   PubMed Web of Science ®Google Scholar
• LiuJLiJLiuNIn vitro studies of phospholipid-modified PAMAM-siMDR1 complexes for the reversal of multidrug resistance in human breast cancer cellsInt J Pharm201753029129928619457
   PubMedGoogle Scholar
• FelkerGMThompsonREHareJMUnderlying causes and long-term survival in patients with initially unexplained cardiomyopathyN Engl J Med20003421077108410760308
   PubMed Web of Science ®Google Scholar
• JonesRLUtility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityExpert Rev Cardiovasc Ther200861311131719018683
   PubMedGoogle Scholar
• ElitokAOzFCizgiciAYEffect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with 6-month follow-upCardiol J20142150951524142687
   PubMed Web of Science ®Google Scholar
• DessyCSallezJGhishdalPEndothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to third-generation beta-blocker nebivololCirculation20051121198120516116070
   PubMed Web of Science ®Google Scholar
• MatsuiHMorishimaINumaguchiYTokiYOkumuraKHayakawaTProtective effects of carvedilol against doxorubicin-induced cardiomyopathy in ratsLife Sci1999651265127410503942
   PubMed Web of Science ®Google Scholar
• NohriaAß-Adrenergic blockade for anthracycline- and trastuzumab-induced cardiotoxicity: is prevention better than cure?Circ Heart Fail2013635836123694770
   PubMed Web of Science ®Google Scholar
• SeiceanSSeiceanAAlanNPlanaJCBuddGTMarwickTHCardioprotective effect of ß-adrenoreceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failureCirc Heart Fail2013642042623425978
   PubMed Web of Science ®Google Scholar
• De NigrisFReienzoMSchianoCFioritoCNapoliCProminent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heartEur J Cancer20084433434018194856
   PubMed Web of Science ®Google Scholar
• KalayNBasarEOzdogruIProtective effects of carvedilol against anthracycline-induced cardiomyopathyJ Am Coll Cardiol2006482258226217161256
   PubMed Web of Science ®Google Scholar